
HIF prolyl-hydroxylase inhibitor - Wikipedia
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a novel class of oral medications developed for the treatment of anemia in chronic kidney disease (CKD).
恩那司他和罗沙司他治疗肾性贫血的疗效对比 - 知乎
促红细胞生成素(EPO)的生成是由低氧诱导因子(HIF)调节,而HIF又是被脯氨酰羟化酶(PH)所调节。 在常氧状态下,HIF-PH的活动将会快速降解HIF;而在低氧条件下,HIF-PH …
缺氧诱导因子(HIF) 是一种关键转录因子,主要参与细胞调节和氧输送效率。 其初步状态包括组成性表达的核结合β 亚基和胞浆α亚基的三种亚型(HIF-1α、HIF-2α 和HIF-3α)。 HIF-1α 和HIF-2 α …
Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the …
The hypoxia-inducible factor (HIF)–prolyl hydroxylase domain (PHD) pathway regulates cellular responses to hypoxia and is involved in multiple diseases, including anemia, polycythemia, …
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A ... - PubMed
Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) enzyme inhibitors are a new class of agents for the treatment of anemia in CKD. These agents work by stabilizing the HIF complex …
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A …
2017年6月1日 · Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) enzyme inhibitors are a new class of agents for the treatment of anemia in CKD. These agents work by stabilizing the …
HIF-α Prolyl Hydroxylase Inhibitors and Their Implications for ...
In this review, I describe the process of molecular cloning of HIF and HIF-PH, which explains the induction of EPO expression by hypoxia; the development of HIF-PH inhibitors (HIF-PHIs) that …
Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm ...
Introduction: The hypoxia-inducible factor prolyl hydroxylase (HIF-PH) pathway is responsible for regulating the biosynthesis of erythropoietin (EPO) and maintaining iron homeostasis. …
HIF-PHI新药罗沙司他,肾性贫血治疗新突破!三生制药SSS-17、 …
2024年3月8日 · 低氧诱导因子(HIF) 是一种参与细胞调控和氧气输送效率的关键转录因子,由调节亚基HIF-α和结构亚基HIF-β构成,当两个亚基形成复合物时,能够激活下游信号通路并诱导 …
HIF-PH阻害薬(腎性貧血治療薬)の解説 - 日経メディカル
血液中には低酸素誘導因子(HIF:Hypoxia Inducible Factor)と呼ばれる酸素濃度の低下を感知する細胞内の酸素センサー的役割を果たしている物質があるが、慢性腎臓病(CKD)の病態 …